Literature DB >> 15353302

Infectious transmission and replication of human T-cell leukemia virus type 1.

David Derse1, Gisela Heidecker, Michael Mitchell, Shawn Hill, Patricia Lloyd, Gerald Princler.   

Abstract

Retrovirus infection proceeds by attachment of the envelope glycoprotein to a cell surface receptor, followed by fusion of the viral and cellular membranes. Once in the cell, the viral enzymes and structural proteins form a replication complex that converts the single-stranded viral genomic RNA into a double-stranded DNA, which is then integrated into the host cell chromosome. For HTLV-1, these events are not well characterized. We have developed cell culture systems, infectious molecular clones, and viral vectors that can be used to characterize the mechanisms of HTLV-1 infection and replication. Infection with cell-free HTLV-1 virions is orders of magnitude less efficient compared with other retroviruses. This inefficiency is the result of a block in the replication process after the virion is bound to the cell surface. We are determining whether this block is conferred by the viral replication enzymes, results from the actions of cellular restriction factors, reflects the need for cell-cell contact, or is caused by a combination of these factors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15353302     DOI: 10.2741/1411

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  9 in total

1.  NF-κB inhibition facilitates the establishment of cell lines that chronically produce human T-lymphotropic virus type 1 viral particles.

Authors:  Muhammad Atif Zahoor; Subha Philip; Huijun Zhi; Chou-Zen Giam
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

2.  C-terminal domain modulates the nucleic acid chaperone activity of human T-cell leukemia virus type 1 nucleocapsid protein via an electrostatic mechanism.

Authors:  Dominic F Qualley; Kristen M Stewart-Maynard; Fei Wang; Mithun Mitra; Robert J Gorelick; Ioulia Rouzina; Mark C Williams; Karin Musier-Forsyth
Journal:  J Biol Chem       Date:  2009-11-03       Impact factor: 5.157

3.  David D. Derse, 1949-2009.

Authors:  Maureen Shuh
Journal:  Retrovirology       Date:  2009-12-01       Impact factor: 4.602

4.  Human T-cell leukemia virus type 1 infection leads to arrest in the G1 phase of the cell cycle.

Authors:  Meihong Liu; Liangpeng Yang; Ling Zhang; Baoying Liu; Randall Merling; Zheng Xia; Chou-Zen Giam
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

Review 5.  HTLV-1 Infection and Adult T-Cell Leukemia/Lymphoma-A Tale of Two Proteins: Tax and HBZ.

Authors:  Chou-Zen Giam; Oliver John Semmes
Journal:  Viruses       Date:  2016-06-16       Impact factor: 5.048

6.  Pseudotyping of HIV-1 with Human T-Lymphotropic Virus 1 (HTLV-1) Envelope Glycoprotein during HIV-1-HTLV-1 Coinfection Facilitates Direct HIV-1 Infection of Female Genital Epithelial Cells: Implications for Sexual Transmission of HIV-1.

Authors:  Yuyang Tang; Alvin M George; Oksana Petrechko; Franklin J Nouvet; Stephanie D Sweet; Yuetsu Tanaka; Brian S Imbiakha; Guochun Jiang; Wei Gao; Kathryn Anastos; James E K Hildreth
Journal:  mSphere       Date:  2018-04-04       Impact factor: 4.389

Review 7.  Is the HTLV-1 Retrovirus Targeted by Host Restriction Factors?

Authors:  Auriane Carcone; Chloé Journo; Hélène Dutartre
Journal:  Viruses       Date:  2022-07-23       Impact factor: 5.818

8.  Induction of galectin-1 expression by HTLV-I Tax and its impact on HTLV-I infectivity.

Authors:  Sonia Gauthier; Isabelle Pelletier; Michel Ouellet; Amandine Vargas; Michel J Tremblay; Sachiko Sato; Benoit Barbeau
Journal:  Retrovirology       Date:  2008-11-25       Impact factor: 4.602

9.  HTLV-1 Tax oncoprotein subverts the cellular DNA damage response via binding to DNA-dependent protein kinase.

Authors:  Sarah S Durkin; Xin Guo; Kimberly A Fryrear; Valia T Mihaylova; Saurabh K Gupta; S Mehdi Belgnaoui; Abdelali Haoudi; Gary M Kupfer; O John Semmes
Journal:  J Biol Chem       Date:  2008-10-27       Impact factor: 5.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.